ArticleMicrobial cell factories2026
Comparative analysis of precursor supply and pathway reinforcement strategies for shikimic acid biosynthesis in Pseudomonas putida.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The shikimate pathway is a central metabolic route for the biosynthesis of high-value aromatic compounds. Traditional metabolic engineering strategies have largely focused on overexpressing pathway-specific genes, enhancing precursor supply, or introducing feedback-resistant variants of 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAHP) synthase to increase pathway flux. However, how these distinct strategies differentially affect flux distribution and the accumulation of key intermediates, specifically 3-dehydroshikimate (DHS) and shikimic acid (SA), remains largely unexplored in Pseudomonas putida (P. putida). Here, we systematically assess the effects of commonly applied engineering strategies on DHS and SA production using distinct SA pathway modules. The results show that overexpression of transketolase I (tktA), phosphoenolpyruvate synthase (ppsA), and SA pathway genes (aroE, aroB, aroQ-II), together with heterologous expression of feedback-resistant aroG, in a genome-edited P. putida EM42 strain harboring pykA/pykF deletions and a hexR knockout, yielded approximately 71 mg L⁻
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.